Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | BPTF | Q12830 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30252450 | 0.79 | GAA (0.38) | GAAALDH1A1LMNAKDM4ENPSR1 | |
| SCHEMBL427846 | 0.79 | GAA (0.38) | GAAALDH1A1LMNAKDM4ENPSR1 | |
| SCHEMBL5334272 | 0.79 | CA1 (0.42) | GAAALDH1A1LMNAKDM4ENPSR1 | |
| SCHEMBL1156253 | 0.79 | GAA (0.38) | GAAALDH1A1LMNAKDM4ENPSR1 | |
| SCHEMBL28259926 | 0.74 | ALDH1A1 (0.36) | ALDH1A1HSD17B10TDP1 | |
| SCHEMBL111337 | 0.72 | — | — | |
| SCHEMBL29367162 | 0.72 | — | — | |
| Ammonia Solution, Strong SCHEMBL25301697 | 0.69 | — | — | |
| SCHEMBL23932032 | 0.69 | TXNRD1 (0.46) | GAAALDH1A1LMNAHTTCYP1A2 | |
| SCHEMBL15200914 | 0.66 | ALDH1A1 (0.33) | GAAALDH1A1HSD17B10TDP1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240150365-A1 | PYRIDINYLSULFONAMIDE COMPOUNDS AND THEIR USE IN THERAPY | HOTSPOT THERAPEUTICS, INC. | 2024-05-09 | — | — | US | disclosed |
| WO-2024044344-A1 | PYRIDINYLSULFONAMIDE COMPOUNDS AND THEIR USE IN THERAPY | HOTSPOT THERAPEUTICS, INC. (US) | 2024-02-29 | — | — | WO | disclosed |
| EP-3655405-B1 | CHEMICAL COMPOUNDS | ANTABIO SAS (FR) | 2023-06-07 | — | — | EP | disclosed |
| US-20220315546-A1 | CHEMICAL COMPOUNDS | ANTABIO SAS (FR) | 2022-10-06 | — | — | US | disclosed |
| US-11299467-B2 | Chemical compounds | ANTABIO SAS (FR) | 2022-04-12 | — | — | US | disclosed |
| US-20200339526-A1 | CHEMICAL COMPOUNDS | ANTABIO SAS (FR) | 2020-10-29 | — | — | US | disclosed |
| EP-3431474-A1 | CHEMICAL COMPOUNDS | Antabio SAS (FR) | 2019-01-23 | — | — | EP | disclosed |
| WO-2013123444-A1 | SULFONYL COMPOUNDS THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN | AMGEN INC. (US) | 2013-08-22 | — | — | WO | disclosed |
| WO-2013123444-A1 | SULFONYL COMPOUNDS THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN | AMGEN INC. (US) | 2013-08-22 | — | — | WO | disclosed |
| EP-2609081-A1 | SULFONYLPIPERAZINE DERIVATIVES THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES | Amgen Inc. (US) | 2013-07-03 | — | — | EP | disclosed |
| US-8431563-B2 | Compounds that interact with glucokinase regulatory protein for the treatment of diabetes | AMGEN INC. (US) | 2013-04-30 | — | — | US | disclosed |
| US-8431563-B2 | Compounds that interact with glucokinase regulatory protein for the treatment of diabetes | AMGEN INC. (US) | 2013-04-30 | — | — | US | disclosed |
| US-8431563-B2 | Compounds that interact with glucokinase regulatory protein for the treatment of diabetes | AMGEN INC. (US) | 2013-04-30 | — | — | US | disclosed |
| US-20120225854-A1 | COMPOUNDS THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES | AMGEN INC. (US) | 2012-09-06 | — | — | US | disclosed |
| US-20120225854-A1 | COMPOUNDS THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES | AMGEN INC. (US) | 2012-09-06 | — | — | US | disclosed |
| US-20120225854-A1 | COMPOUNDS THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES | AMGEN INC. (US) | 2012-09-06 | — | — | US | disclosed |
| WO-2012027261-A1 | SULFONYLPIPERAZINE DERIVATIVES THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES | AMGEN INC. (US) | 2012-03-01 | — | — | WO | disclosed |
| WO-2007034282-A2 | DIARYL-IMIDAZOLE COMPOUNDS CONDENSED WITH A HETEROCYCLE AS C3A RECEPTOR ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2007-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220315546-A1 | CHEMICAL COMPOUNDS | MRPL21, MLX, TXN | GAA 2518/4885ALDH1A1 1565/4885HSD17B10 3379/4885 |
| US-11299467-B2 | Chemical compounds | MRPL21, MLX, CFTR | GAA 2286/4885ALDH1A1 1225/4885HSD17B10 3240/4885 |
| US-20200339526-A1 | CHEMICAL COMPOUNDS | MRPL21, MLX, CFTR | GAA 2286/4885ALDH1A1 1225/4885HSD17B10 3240/4885 |
| US-20120225854-A1 | COMPOUNDS THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES | GCKR, GCK, SLC5A2 | GAA 455/4885ALDH1A1 3293/4885HSD17B10 1194/4885 |
| US-20240150365-A1 | PYRIDINYLSULFONAMIDE COMPOUNDS AND THEIR USE IN THERAPY | MALT1, BCL6, BCL6B | GAA 2769/4885ALDH1A1 3059/4885HSD17B10 3540/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.